ODI Law has advised Slovenian diagnostic system manufacturer Mesi on a strategic investment from Heine Optotechnik CEO Oliver Heine. EY Law Germany reportedly advised the investor.
According to Mesi, Heine joins the company as a new investor and strategic advisor to accelerate growth, with the goal of increasing the number of Mesi mTablet users to more than 100,000 over the next few years.
Mesi is a Slovenian company providing clinicians with predictive medical assessment devices, aiming to empower first-contact care to diagnose diseases early and provide on-time treatment.
Heine Optotechnik is a German diagnostic instruments manufacturer. The company is present in 120 countries around the world, with subsidiaries in Australia, the US, Canada, and Switzerland.
“Mesi is digitalizing the medical practice with the latest benefits that digital technology and AI have to offer,” Heine commented. “An all-in-one diagnostic measurement system, automatic administration, and the instant recording of results are just some examples. I look forward to advising the Mesi team as they strive to make the work of healthcare professionals faster and more effective.”
“Welcoming Oliver Heine as an investor and board member is a great honor,” Mesi CEO Jakob Susteric added. “Heine Optotechnik has been synonymous with product quality for more than 75 years. Our common values are sustainability, customer commitment, and timely diagnostics for effective treatment. The strategic partnership with a visionary like Heine is proof that our efforts have been recognized at a global level.”
The ODI team was led by Senior Associate Primoz Mikolic and included Senior Associate Klemen Kos and Associate Eva Hafnar.